The tweet was deleted by the author.
But we saved everything 🙂.
Lexicon Pharmaceuticals is rallying support to raise awareness for hypertrophic cardiomyopathy (HCM), a genetic heart condition with limited treatment options.
The company has reaffirmed its commitment to advancing new therapies for HCM patients, highlighting the urgent unmet medical needs faced by this community. Lexicon Pharmaceuticals is actively working to develop solutions, reinforcing its focus on addressing rare cardiovascular diseases. Details on clinical progress or product timelines were not disclosed. Details are being clarified.